This is a continuation of a long topic, addressed by post number rather than by page. Start at post 1.
The mass figure differs between sources because of how the different entities report it. The monoisotopic mass of the bare peptide is one number; the mass including the acylation is another. Different sources emphasise different details.
If this contradicts something upthread, the upthread version may well be the better one.
Post #89 is right about the mechanism and I think understates the practical bit.
Two sentences on Semaglutide half-life and then I will stop, because the rest is speculation and the thread is better without mine.
What is documented is narrow. What is inferred from it is broad. The gap between them is where every argument here lives.
A definition problem is doing most of the work in this Semaglutide half-life discussion. Once the term is pinned down I suspect the disagreement mostly goes away and what is left is small.
On the injection-day question: the labelling for licensed semaglutide allows the day to be changed provided at least two days separate the two injections. That interval is not arbitrary — it is what stops two doses stacking inside one absorption window.
This is the version I would want a new member to read first.
Discontinuation rates in the trials are worth reading alongside efficacy and almost never are. A large mean effect in a population where a meaningful fraction stopped early is telling you two things, not one.
I am aware this is the third time this month I have made this point.
Post #93 and I disagree about the size of the effect, not about the direction.
The C-cell question: semaglutide triggered medullary thyroid carcinoma in rodent toxicology studies. A signal in rodents does not automatically appear in humans, but it is the reason the compound is contraindicated in people with personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2.
Semaglutide half-life was covered in the wiki last year and the page has a review date on it, which is a better starting point than my memory of a thread.
Everything in post #97 holds. The case it does not cover is the one I have.
Semaglutide half-life has a well-known answer and a correct answer, and the interesting work is establishing that they are the same. Nobody has done that here yet.
On alcohol: the labelling does not contraindicate it, but it raises gastric irritation risk and semaglutide already does that. There is no published interaction study and the conservative position is to limit it if you are titrating or if gastrointestinal symptoms are troublesome.
Written in the hope of being told what I have missed.
Injection site does not appear to matter much for semaglutide exposure. The published comparisons of abdomen, thigh and upper arm found differences small enough to be clinically unimportant, which is not true of every injectable.
I have kept the units in throughout, for the obvious reason.
Picking up post #101: that is the part I would want checked first.
Semaglutide's structure is a modified backbone with a C18 diacid attached through a spacer. The acylation is the reason for the long half-life and it is also the reason a plain sequence comparison against native GLP-1 is misleading about how the molecule behaves.
Not the answer, but possibly the question that gets there.
What would change my mind on Semaglutide half-life is a second dataset collected by someone with no stake in the first. Until then I hold it loosely and I would rather say so than pretend to more.
Worth separating two things that post #101 runs together.
On identity confirmation: a mass close to 4113.6 Da on the intact molecule is consistent with semaglutide and is also consistent with several closely related species. Mass narrows the field; it does not close it, and no certificate should be read as though it did.
The number is defensible. The precision I gave it is not.
This follows post #105 rather than contradicting it.
Semaglutide versus liraglutide in STEP 8: semaglutide produced greater weight reduction and the discontinuation rates differed. But the trial was open-label for the dosing schedule, which admits expectation effects. Weekly versus daily itself is part of the comparison, not a confounding variable to be removed.
Reporting the observation and leaving the explanation open deliberately.
Following this. I have the same question and no better information than the first post.
The opalescent appearance in semaglutide solutions is occasionally noted and the mechanism is unclear. It does not appear to correlate with product failure in practice. Visible particles or frank cloudiness is different and would be reason to contact the supplier.
The arithmetic in post #109 is right; the assumption feeding it is the part to check.
The mass figure differs between sources because of how the different entities report it. The monoisotopic mass of the bare peptide is one number; the mass including the acylation is another. Different sources emphasise different details.
This is the sort of thing the wiki should carry and currently does not.
On alcohol: the labelling does not contraindicate it, but it raises gastric irritation risk and semaglutide already does that. There is no published interaction study and the conservative position is to limit it if you are titrating or if gastrointestinal symptoms are troublesome.
On identity confirmation: a mass close to 4113.6 Da on the intact molecule is consistent with semaglutide and is also consistent with several closely related species. Mass narrows the field; it does not close it, and no certificate should be read as though it did.
I would want to see it done twice before believing it once.
Where I part company with post #110, and it is a narrow parting.
One more thing on Semaglutide half-life that took me far too long to see: the two figures people quote are not measuring the same quantity. Once you notice that, the apparent contradiction disappears.
This is the sort of exchange that makes the archive worth searching.
Semaglutide's structure is a modified backbone with a C18 diacid attached through a spacer. The acylation is the reason for the long half-life and it is also the reason a plain sequence comparison against native GLP-1 is misleading about how the molecule behaves.
Confirming post #116 from a second method, which matters more than confirming it from a second person.
Since Semaglutide half-life keeps coming up, it should probably be a maintained page rather than a recurring thread. I am happy to draft it if someone with more direct experience will review it.
I had written a reply contradicting post #114 and deleted it. Here is what survived.
Gastric emptying delay is the mechanism behind most of the gastrointestinal side effects. Slowing the stomach empties it feeds less food into the intestines at a time, which is part of the satiety mechanism but is also why nausea is dose-dependent and titration-dependent.
That distinction has done more work for me than anything else in this category.
I read post #118 twice before replying, because I had assumed the opposite.
On Semaglutide half-life I would separate what is worth knowing from what is worth acting on. The first list is long and the second is short, and conflating them is how threads get heated.